News >

Brigatinib Elicits Responses in ALK+ NSCLC Following Next-Generation TKIs

Lisa Astor
Published: Friday, Jun 07, 2019

Thomas E. Stinchcombe, MD

Thomas E. Stinchcombe, MD

Brigatinib (Alunbrig) demonstrated promising response rates in patients with ALK-positive non–small cell lung cancer (NSCLC) who have progressed on treatment with another next-generation ALK TKI, according to preliminary phase II results presented at the 2019 ASCO Annual Meeting.1

 
References
  1. Stinchcombe T, Doebele RC, Wang XF, et al. Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(suppl; abstr 9027). meetinglibrary.asco.org/record/174623/abstract.
  2. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(2:2490-2498. doi: 10.1200/JCO.2016.71.5904.
  3. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027-2039. doi: 10.1056/NEJMoa1810171.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x